Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP

Pharmaceutical Biology · Published 2026-06-27 · DOI 10.1080/13880209.2026.2693375

Free full text

Authors (9)

Nadeem Akhtar, Joanne Barnes, Paula Gardiner, Bill J. Gurley, Richard Ko, Igor Koturbash, Deval Patel, Richard B. van Breemen, Amy L. Roe

Abstract

Background The United States Pharmacopeia (USP) Dietary Supplement Admission Evaluation and Labeling Expert Committee (DSAEL EC) routinely monitors safety‑related literature for dietary ingredients covered by USP monographs. Following multiple reports of hepatotoxicity associated with turmeric- or curcuminoid-containing products, the DSAEL EC conducted a comprehensive evaluation.Objective To assess the safety of turmeric and curcuminoids and determine whether cautionary labeling should be added to the USP monographs for these ingredients.Methods Following USP Guidelines, the DSAEL EC reviewed safety and toxicological information.Results and Discussion Hepatotoxicity has been observed with high-dose turmeric rhizome powder or extract in a few rodent toxicology studies. Numerous clinical trials involving turmeric- or curcuminoid-containing supplements have not reported organ toxicity or serious adverse events. Published case reports of clinically apparent liver injury often involve concomitant medications or supplements. Reported hepatotoxicity typically occurs after 1 to 4 months of use and generally resolves upon discontinuation; cases of acute liver failure have been reported albeit rarely. Proposed mechanisms include idiosyncratic, immune-mediated injury, and emerging evidence suggests possible genetic susceptibility.Conclusions The USP DSAEL EC recommends adding the following cautionary statement to its turmeric and curcuminoids monographs: Liver problems have been reported very rarely in people taking supplements containing turmeric and/or curcuminoids. Consult your health-care practitioner before using this product if you have a history of liver problems. Stop using this product if you develop symptoms such as abdominal pain, dark urine, or jaundice (yellowing of the skin or eyes), and seek medical advice.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year
2026

Citation

Akhtar, N., Barnes, J., Gardiner, P., et al. (2026). Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. Pharmaceutical Biology. https://doi.org/10.1080/13880209.2026.2693375

Related articles